BRAF and neoplasm: Although these compounds had comparable binding capacity to BRAF-V600E in vitro (Vemurafenib = 27 nM, SJF-0628 = 39 nM, SJF-0661 = 64 nM), SJF-0628 had significantly stronger anti-tumor activity.